A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks

NCT01560286 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Phenylketonuria

Interventions

BIOLOGICAL: BMN 165 (rAvPAL-PEG)

Sponsor

BioMarin Pharmaceutical